GlaxoSmithKline Change In Cash vs Change To Liabilities Analysis

GSK Stock

1,340 3.50 0.26%

GlaxoSmithKline PLC financial indicator trend analysis is much more than just examining GlaxoSmithKline PLC latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GlaxoSmithKline PLC is a good investment. Please check the relationship between GlaxoSmithKline PLC Change In Cash and its Change To Liabilities accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Change In Cash vs Change To Liabilities

Change In Cash vs Change To Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GlaxoSmithKline PLC Change In Cash account and Change To Liabilities. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between GlaxoSmithKline PLC's Change In Cash and Change To Liabilities is -0.14. Overlapping area represents the amount of variation of Change In Cash that can explain the historical movement of Change To Liabilities in the same time period over historical financial statements of GlaxoSmithKline PLC, assuming nothing else is changed. The correlation between historical values of GlaxoSmithKline PLC's Change In Cash and Change To Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change In Cash of GlaxoSmithKline PLC are associated (or correlated) with its Change To Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change To Liabilities has no effect on the direction of Change In Cash i.e., GlaxoSmithKline PLC's Change In Cash and Change To Liabilities go up and down completely randomly.

Correlation Coefficient

-0.14

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Change In Cash

Change To Liabilities

Most indicators from GlaxoSmithKline PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GlaxoSmithKline PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At present, GlaxoSmithKline PLC's Discontinued Operations is projected to increase significantly based on the last few years of reporting.

	2021	2022	2023	2024 (projected)
Interest Expense	784M	879M	775M	502.2M
Depreciation And Amortization	2.1B	2.1B	2.3B	1.2B

Interest Expense Depreciation And Amortization

GlaxoSmithKline PLC fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Retained Earnings	Net Receivables
Total Assets		0.92	0.21	0.89	0.5	0.89	0.9	0.33	0.61	0.99	0.37	0.59	0.7	0.36	-0.07	0.95	0.95	-0.07	0.68	0.97	0.34	0.91	0.71	0.7	0.12	0.78
Short Long Term Debt Total	0.92		0.08	0.83	0.41	0.88	0.98	0.41	0.65	0.9	0.35	0.56	0.71	0.42	-0.15	0.91	0.9	0.09	0.71	0.91	0.25	0.87	0.87	0.73	0.03	0.71
Other Current Liab	0.21	0.08		0.08	0.78	0.12	0.04	-0.62	0.19	0.16	0.29	0.54	0.37	0.34	0.52	0.04	0.16	-0.38	-0.25	0.06	0.48	0.36	-0.21	0.34	0.67	0.08
Total Current Liabilities	0.89	0.83	0.08		0.3	0.89	0.83	0.53	0.45	0.87	0.49	0.53	0.72	0.42	0.05	0.83	0.94	0.07	0.78	0.94	0.38	0.87	0.72	0.71	-0.07	0.85
Total Stockholder Equity	0.5	0.41	0.78	0.3		0.27	0.43	-0.44	0.19	0.49	0.2	0.43	0.37	0.33	0.39	0.29	0.35	-0.6	-0.02	0.31	0.57	0.48	0.25	0.33	0.88	0.46
Property Plant And Equipment Net	0.89	0.88	0.12	0.89	0.27		0.83	0.56	0.74	0.84	0.34	0.66	0.9	0.62	-0.12	0.91	0.97	0.34	0.82	0.94	0.43	0.93	0.71	0.91	-0.2	0.76
Net Debt	0.9	0.98	0.04	0.83	0.43	0.83		0.38	0.5	0.89	0.37	0.46	0.64	0.36	-0.09	0.87	0.87	-0.01	0.7	0.89	0.27	0.82	0.9	0.65	0.08	0.74
Accounts Payable	0.33	0.41	-0.62	0.53	-0.44	0.56	0.38		0.33	0.33	0.01	0.0	0.38	0.32	-0.42	0.44	0.48	0.63	0.75	0.5	0.06	0.3	0.49	0.43	-0.71	0.45
Cash	0.61	0.65	0.19	0.45	0.19	0.74	0.5	0.33		0.56	0.1	0.71	0.71	0.51	-0.37	0.68	0.64	0.46	0.44	0.61	0.09	0.72	0.37	0.77	-0.18	0.31
Non Current Assets Total	0.99	0.9	0.16	0.87	0.49	0.84	0.89	0.33	0.56		0.32	0.5	0.62	0.28	-0.12	0.94	0.92	-0.12	0.65	0.95	0.3	0.85	0.7	0.63	0.13	0.77
Non Currrent Assets Other	0.37	0.35	0.29	0.49	0.2	0.34	0.37	0.01	0.1	0.32		0.59	0.28	0.24	0.65	0.33	0.39	-0.15	0.34	0.41	0.05	0.52	0.33	0.32	0.04	0.33
Cash And Short Term Investments	0.59	0.56	0.54	0.53	0.43	0.66	0.46	0.0	0.71	0.5	0.59		0.75	0.63	0.37	0.57	0.64	0.07	0.37	0.58	0.33	0.84	0.32	0.75	0.11	0.38
Common Stock Total Equity	0.7	0.71	0.37	0.72	0.37	0.9	0.64	0.38	0.71	0.62	0.28	0.75		0.79	0.06	0.69	0.83	0.36	0.66	0.73	0.62	0.88	0.52	0.98	-0.08	0.64
Common Stock Shares Outstanding	0.36	0.42	0.34	0.42	0.33	0.62	0.36	0.32	0.51	0.28	0.24	0.63	0.79		0.28	0.38	0.49	0.33	0.54	0.41	0.75	0.6	0.38	0.8	-0.04	0.53
Short Term Investments	-0.07	-0.15	0.52	0.05	0.39	-0.12	-0.09	-0.42	-0.37	-0.12	0.65	0.37	0.06	0.28		-0.18	-0.05	-0.48	-0.09	-0.09	0.41	0.13	-0.09	0.0	0.42	0.12
Non Current Liabilities Total	0.95	0.91	0.04	0.83	0.29	0.91	0.87	0.44	0.68	0.94	0.33	0.57	0.69	0.38	-0.18		0.94	0.14	0.76	0.97	0.27	0.87	0.71	0.71	-0.12	0.7
Inventory	0.95	0.9	0.16	0.94	0.35	0.97	0.87	0.48	0.64	0.92	0.39	0.64	0.83	0.49	-0.05	0.94		0.15	0.77	0.98	0.41	0.94	0.7	0.82	-0.08	0.78
Other Current Assets	-0.07	0.09	-0.38	0.07	-0.6	0.34	-0.01	0.63	0.46	-0.12	-0.15	0.07	0.36	0.33	-0.48	0.14	0.15		0.4	0.11	-0.07	0.1	0.1	0.43	-0.82	-0.02
Other Stockholder Equity	0.68	0.71	-0.25	0.78	-0.02	0.82	0.7	0.75	0.44	0.65	0.34	0.37	0.66	0.54	-0.09	0.76	0.77	0.4		0.8	0.32	0.68	0.77	0.69	-0.38	0.77
Total Liab	0.97	0.91	0.06	0.94	0.31	0.94	0.89	0.5	0.61	0.95	0.41	0.58	0.73	0.41	-0.09	0.97	0.98	0.11	0.8		0.33	0.91	0.75	0.74	-0.11	0.79
Property Plant And Equipment Gross	0.34	0.25	0.48	0.38	0.57	0.43	0.27	0.06	0.09	0.3	0.05	0.33	0.62	0.75	0.41	0.27	0.41	-0.07	0.32	0.33		0.44	0.21	0.54	0.3	0.6
Total Current Assets	0.91	0.87	0.36	0.87	0.48	0.93	0.82	0.3	0.72	0.85	0.52	0.84	0.88	0.6	0.13	0.87	0.94	0.1	0.68	0.91	0.44		0.65	0.88	0.06	0.73
Short Term Debt	0.71	0.87	-0.21	0.72	0.25	0.71	0.9	0.49	0.37	0.7	0.33	0.32	0.52	0.38	-0.09	0.71	0.7	0.1	0.77	0.75	0.21	0.65		0.55	-0.03	0.76
Common Stock	0.7	0.73	0.34	0.71	0.33	0.91	0.65	0.43	0.77	0.63	0.32	0.75	0.98	0.8	0.0	0.71	0.82	0.43	0.69	0.74	0.54	0.88	0.55		-0.14	0.63
Retained Earnings	0.12	0.03	0.67	-0.07	0.88	-0.2	0.08	-0.71	-0.18	0.13	0.04	0.11	-0.08	-0.04	0.42	-0.12	-0.08	-0.82	-0.38	-0.11	0.3	0.06	-0.03	-0.14		0.14
Net Receivables	0.78	0.71	0.08	0.85	0.46	0.76	0.74	0.45	0.31	0.77	0.33	0.38	0.64	0.53	0.12	0.7	0.78	-0.02	0.77	0.79	0.6	0.73	0.76	0.63	0.14

Click cells to compare fundamentals

GlaxoSmithKline PLC Account Relationship Matchups

GlaxoSmithKline PLC fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	79.7B	80.4B	79.1B	60.1B	59.0B	32.8B
Short Long Term Debt Total	30.5B	27.2B	24.2B	21.0B	18.0B	11.0B
Other Current Liab	755M	13.2B	14.7B	14.2B	13.8B	14.5B
Total Current Liabilities	24.1B	22.1B	23.7B	22.8B	21.1B	11.2B
Total Stockholder Equity	12.0B	14.6B	15.1B	10.6B	13.3B	14.0B
Property Plant And Equipment Net	11.3B	11.0B	10.7B	9.6B	10.0B	7.1B
Net Debt	25.8B	20.9B	19.9B	17.3B	15.1B	8.3B
Accounts Payable	14.9B	4.4B	4.5B	3.9B	3.7B	5.0B
Cash	4.7B	6.3B	4.3B	3.7B	2.9B	2.7B
Non Current Assets Total	60.2B	60.2B	60.4B	39.4B	40.4B	20.9B
Non Currrent Assets Other	1.2B	1.1B	1.8B	5.3B	634M	1.0B
Cash And Short Term Investments	4.8B	6.4B	4.3B	7.9B	5.7B	3.9B
Common Stock Shares Outstanding	4.0B	4.0B	3.2B	4.1B	4.1B	4.7B
Liabilities And Stockholders Equity	79.7B	80.4B	79.1B	60.1B	59.0B	32.8B
Non Current Liabilities Total	37.3B	37.5B	34.1B	27.2B	25.1B	14.3B
Inventory	5.9B	6.0B	5.8B	5.1B	5.5B	3.0B
Other Current Assets	1.6B	1.9B	1.7B	1.4B	1.6B	2.8B
Other Stockholder Equity	4.9B	3.1B	3.3B	3.7B	3.2B	2.9B
Total Liab	61.3B	59.6B	57.8B	50.1B	46.2B	25.5B
Property Plant And Equipment Gross	11.3B	11.0B	10.7B	9.6B	20.2B	21.2B
Total Current Assets	19.5B	20.2B	18.7B	20.8B	18.6B	11.9B
Short Term Debt	6.9B	3.7B	3.6B	4.0B	2.8B	2.2B
Common Stock	1.3B	1.3B	1.3B	1.3B	1.3B	1.3B
Retained Earnings	5.1B	6.8B	7.9B	4.4B	7.2B	7.6B
Net Receivables	7.1B	5.5B	6.2B	5.5B	5.9B	5.7B
Accumulated Other Comprehensive Income	641M	1.6B	642M	(48M)	1.6B	1.7B
Intangible Assets	31.0B	29.8B	30.1B	14.3B	14.8B	11.4B
Other Liab	13.7B	14.1B	13.5B	10.2B	11.7B	8.0B
Other Assets	5.1B	5.3B	6.9B	6.8B	7.8B	4.3B
Long Term Debt	22.6B	22.5B	19.8B	16.2B	14.2B	13.5B
Good Will	10.6B	10.6B	10.6B	7.0B	6.8B	4.4B
Property Plant Equipment	11.3B	11.0B	10.7B	9.6B	11.1B	9.7B
Current Deferred Revenue	1.4B	1.8B	1.6B	299M	222M	233.1M
Net Tangible Assets	(30.1B)	(25.8B)	(25.6B)	(10.8B)	(9.7B)	(10.2B)
Short Long Term Debt	6.7B	3.5B	3.4B	3.8B	2.7B	3.9B
Capital Surpluse	3.0B	3.1B	3.2B	3.3B	3.8B	3.4B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Other Information on Investing in GlaxoSmithKline Stock

Balance Sheet is a snapshot of the financial position of GlaxoSmithKline PLC at a specified time, usually calculated after every quarter, six months, or one year. GlaxoSmithKline PLC Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of GlaxoSmithKline PLC and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which GlaxoSmithKline currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

GlaxoSmithKline Change In Cash vs Change To Liabilities Analysis

Change In Cash vs Change To Liabilities

Change In Cash vs Change To Liabilities Correlation Analysis

Correlation Coefficient

Change In Cash

Change To Liabilities

GlaxoSmithKline PLC fundamental ratios Correlations

GlaxoSmithKline PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

GlaxoSmithKline PLC fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in GlaxoSmithKline Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 0.99	Total Assets
Net Debt	+ 0.98	Short Long Term Debt Total
Common Stock	+ 0.98	Common Stock Total Equity
Total Liab	+ 0.98	Inventory
Total Liab	+ 0.97	Total Assets
Inventory	+ 0.97	Property Plant And Equipment Net

Retained Earnings	- 0.82	Other Current Assets
Retained Earnings	- 0.71	Accounts Payable
Accounts Payable	- 0.62	Other Current Liab
Other Current Assets	- 0.6	Total Stockholder Equity
Other Current Assets	- 0.48	Short Term Investments
Accounts Payable	- 0.44	Total Stockholder Equity